Magenta Therapeutics Appoints Jason Ryan as Chief Operating and Financial Officer

From Startup Magenta Therapeutics

Link to Full Article: https://investor.magentatx.com/news-releases/news-release-details/magenta-therapeutics-appoints-jason-ryan-chief-operating-and

CAMBRIDGE, Mass.–(BUSINESS WIRE)–Nov. 19, 2018–
Magenta
Therapeutics (NASDAQ: MGTA), a clinical-stage biotechnology company
developing novel medicines to bring the curative power of bone marrow
transplant to more patients, today announced that it has strengthened
its executive team with the appointment of Jason Ryan as Chief Operating
and Financial Officer, effective January 1, 2019.

“We are delighted to welcome Jason to Magenta at such an important time
for the Company,” said Jason Gardner, D.Phil., chief executive officer
and president, Magenta Therapeutics. “As we grow as a public company and
advance our portfolio, Jason’s depth of experience in capital creation
and allocation, operations and finance, and commercial planning will
nicely complement the skills of our existing team and position us well
to bring our first-in-class therapies to patients as efficiently and
effectively as possible. I am looking forward to working closely with
Jason in this high-impact role for our business.”

Mr. Ryan joins Magenta from Foundation Medicine, where he served as
chief financial officer. During his tenure at Foundation, Mr. Ryan
helped lead the company from early stage proof of concept to a global
commercial organization. He was responsible for long-range planning and
capital formation, and he played a key role in the company’s
relationship with, and sale to, Roche in July 2018. He also worked
closely with the company’s commercial leadership through several product
launches and was deeply involved in Medicare and commercial payer
reimbursement strategy and execution. Prior to that, Mr. Ryan held
management positions for Taligen Therapeutics, Codon Devices and
Genomics Collaborative, and began his career at Deloitte & Touche. Mr.
Ryan holds a B.S. in economics from Bates College and an M.B.A. from
Babson College.

About Magenta TherapeuticsHeadquartered in Cambridge,
Mass., Magenta Therapeutics is a clinical-stage biotechnology company
developing novel medicines for patients with autoimmune diseases, blood
cancers and genetic diseases. By creating a platform focused on critical
areas of unmet need, Magenta Therapeutics is pioneering an integrated
approach to allow more patients to receive one-time, curative therapies
by making the process more effective, safer and easier.

Forward-Looking StatementThis press release may contain
forward-looking statements, including express or implied statements
regarding Magenta’s future expectations, plans and prospects, including
projections regarding future revenues and financing performance, our
long-term growth, the anticipated timing of our clinical trials and
regulatory filings, the development of our product candidates and
advancement of our preclinical programs, as well as other statements
containing the words “anticipate,” “believe,” “continue,” “could,”
“estimate,” “expect,” “intend,” “may,” might,” “plan,” “potential,”
“project,” “should,” target,” “will” or “would” and similar expressions
that constitute forward-looking statements under the Private Securities
Litigation Reform Act of 1995. Although Magenta’s forward-looking
statements reflect the good faith judgment of its management, these
statements are based only on facts and factors currently known by
Magenta. As a result, you are cautioned not to rely on these
forward-looking statements. These and other risks concerning Magenta’s
programs and operations are described in additional detail in its
registration statement on Form S-1, its Quarterly Report on Form 10-Q
and its other filings made with the Securities and Exchange Commission
from time to time. Any forward-looking statement made in this press
release speaks only as of the date on which it is made. Magenta
undertakes no obligation to publicly update or revise any
forward-looking statement, whether as a result of new information,
future developments or otherwise.

View source version on businesswire.com: https://www.businesswire.com/news/home/20181119005148/en/
Source: Magenta Therapeutics

Magenta Therapeutics:Manisha PaiVice President,
Communications & Investor Relations617-510-9193mpai@magentatx.com

Please visit their site for more information: Magenta Therapeutics.com

All,Biotechnology,Healthcare News,Startup News
2018-11-19 20:11:04